| Literature DB >> 21206659 |
Abstract
Laparoscopic adrenalectomy is currently recognized as the gold standard for the treatment of adrenal tumors. In order to assess the current status of laparoscopic adrenalectomy, we reviewed the literature focusing on the indications and contraindications, surgical techniques, complications and new methods. We also reviewed the results separately for aldosteronoma, pheochromocytoma, Cushing's syndrome, and primary or metastatic adrenal cancer.Laparoscopic adrenalectomy is a safe and effective treatment for adrenal disorders, excluding primary adrenal cancer. There are no differences of the various operative parameters between the transperitoneal and retroperitoneal approaches, so the choice of approach should depend on the surgeon's preference or the patient's circumstances. It is important for the surgeon to remove the tumor and the surrounding fat en bloc, especially in the case of large or irregular tumors because of the potential for malignancy. The surgeon must also immediately switch to an open procedure if the laparoscopic operation becomes difficult.We conclude that use of laparoscopic adrenalectomy allows the performance of minimally invasive surgery with the advantages of more rapid recovery and a shorter hospital stay than open adrenalectomy.Entities:
Keywords: Cushing's syndrome; adrenal cancer; adrenalectomy; aldosteronoma; pheochromocytoma
Year: 2005 PMID: 21206659 PMCID: PMC3004118 DOI: 10.4103/0972-9941.19263
Source DB: PubMed Journal: J Minim Access Surg ISSN: 1998-3921 Impact factor: 1.407
Figure 1Trocar positions: 10-mm trocar for the laparoscope. A and B: 5-mm trocars for the surgeon. C: 5-mm trocar for the assistant (if necessary). MCL, middle clavicular line. MAL, midaxillary line.
Laparoscopic adrenalectomy for aldosteronoma
| References | No. Pts. | Mean Age | Approach (No.) | Mean Ope. Time (mins.) | EBL (cc) | No. Comversion | No. Complications | Hospital stay (days) | No. Cures Hypertension | Tumor size (cm.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Brunt et al.[ | 29 | 48 | Transperitoneal | 148 | 60 | 0 | 6 (20%) | 2.2 | 8/26 (31%) (improved; 92%) | 1.9 |
| Harris et al.[ | 21 | 48 | Transperitoneal | 158 | 1.92 (9.5%) | 0 | 3.1 | 13/21 (62%·j | ||
| Rossi et al.[ | 30 | 51.2 | Transperitoneal | 183 | 1 (3.3%) | 2 (6.7%) | 2.2 | 20/30 (67%) (improved; 97% | 2 | |
| Ishidoya et al.[ | 63 | 50.2 | Transperitoneal (21) | |||||||
| Retroperitoneal (42) | 199 | 57.3 | 0 | improved; All | 1.6 | |||||
| Kalady et al.[ | 27 | 47 | Transperitoneal | 153 | 88 | 4 (14.8%) | 2 (7.4%) | 3.6 | 3.3 | |
| Overall | 170 | 49.2 | Transperitoneal (128) | |||||||
| Retroperitoneal (42) | 175 | 45 | 7 (4.1%) | 10/107 (9.3%) | 2.7 | 42/77 (54.5%) (improved; 98%) | 2 |
Laparosacopic adrenalectomy for pheochromocytoma
| References | No. Pts. | Mean Age | Approach (No.) | Mean Ope. Time (mins.) | EBL (cc) | No. Comversion | No. Complications | Hospital stay (days) | Tumor size (cm.) |
|---|---|---|---|---|---|---|---|---|---|
| Brunt et al.[ | 35 | 42 | Transperitoneal | 208 | 147 | 2 (5.7%) | 7 (22.9%) | 3.4 | 3.4 |
| Kazaryan et al.[ | 9 | 48 | Transperitoneal | 132 | 178 | 0 | 0 | 3.2 | 6.4 |
| Kim et al.[ | 15 | 45.2 | Transperitoneal | 171 | 189.5 | 0 | 0 | 5.6 | 5.2 |
| Flavio Rocha et al.[ | 12 | 54 | Transperitoneal (11) | ||||||
| Retroperitoneal (2) | 127 | 105 | 0 | 4.18 | 4.4 | ||||
| Kalady et al.[ | 28 | 53 | Transperitoneal | 181 | 150 | 3 (10.7%) | 3 (10.7%) | 3.7 | 5.2 |
| Bentrem et al.[ | 4 | 43 | Transperitoneal | 218 | 188 | 3 | 4.3 | ||
| Thomson et al.[ | 18 | 48 | Transperitoneal | 180 (unilateral) | |||||
| 450 (bilateral) | 200 | 2 (10.5%) | 6 (33.3%) | 5 | 6 | ||||
| Overall | 121 | 47.5 | Transperitoneal (119) | ||||||
| Retroperitoneal (2) | 180 | 160 | 7/105 (6.7%) | 16/117 (13.7%) | 4 | 4.8 |